Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control group | Active Comparator | patients were on sitagliptin 100mg /day monotherapy |
|
| Comparative group | Active Comparator | patients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sitagliptin 100mg | Drug | Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in glycemic profile | measurement of fasting blood glucose (FBG) | 3 months |
| Change in glycemic profile | measurement of glycated hemoglobin | 3 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tanta Unuversity | Recruiting | Tanta | 31527 | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42271067 | Derived | El-Khateeb E, Khrieba MO, Badawoud AM, Morsy AA, El-Hanafy AA, Hamza E, Habba E, El-Hanafy DA, Eltantawy N, Al-Dhelaan RA, Radwan KH, El-Sayed AA, Eladaroussay MM, Rizk KAK, Ebrahim MHE, Abd Elhameed AG, Erfan EA, Elkhodary NM, Elshorbagi N, Sami HM, Dewidar SA, Mahdy MA, Zakaria H. Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes. Naunyn Schmiedebergs Arch Pharmacol. 2026 Jun 11. doi: 10.1007/s00210-026-05510-7. Online ahead of print. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068900 | Sitagliptin Phosphate |
| D004318 | Doxycycline |
| ID | Term |
|---|---|
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
open label
Not provided
Not provided
open label
Not provided
| Doxycyclin | Drug | Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth. |
|
| D004700 | Endocrine System Diseases |
| D011719 |
| Pyrazines |
| D013754 | Tetracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |